6-Methyl-1-oxido-pyrazin-1-ium-2-carboxylic acid | 914225-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-Methyl-1-oxido-pyrazin-1-ium-2-carboxylic acid
• 英文别名: 6-methyl-1-oxidopyrazin-1-ium-2-carboxylic acid
• CAS: 914225-75-5
• 化学式: C6H6N2O3
• 分子量: 154.12
• InChiKey: DNRXJHATQULEHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
  申请人：G.D. Searle LLC

  公开号：EP1340508A1

  公开（公告）日：2003-09-03

  The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a nicotinic acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.

  本发明提供了用于预防或治疗心血管疾病（包括高胆固醇血症、动脉粥样硬化或高脂血症）的心血管治疗化合物组合。公开的组合物包括烟酸衍生物与胆固醇酯转移蛋白（CETP）抑制剂的组合。
• COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
  申请人：G.D. Searle LLC

  公开号：EP1140184B1

  公开（公告）日：2003-06-04
• COMBINATIONS OF ILEAL BILE ACID TRANSPORT INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
  申请人：G.D. Searle LLC

  公开号：EP1140191B1

  公开（公告）日：2002-10-23
• EP2576778B1
  申请人：——

  公开号：EP2576778B1

  公开（公告）日：2017-08-09
• Combination of an aldosterone receptor antagonist and an anti-diabetic agent
  申请人：Gulve Arthur Eric

  公开号：US20050014732A1

  公开（公告）日：2005-01-20

  A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an anti-diabetic agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred antidiabetic agents are those compounds having high potency and oral or parenteral bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α,11α-substituted epoxy moiety.